WO2004063165A1 - A pyrazole derivative as ppar modulator - Google Patents
A pyrazole derivative as ppar modulator Download PDFInfo
- Publication number
- WO2004063165A1 WO2004063165A1 PCT/US2003/039117 US0339117W WO2004063165A1 WO 2004063165 A1 WO2004063165 A1 WO 2004063165A1 US 0339117 W US0339117 W US 0339117W WO 2004063165 A1 WO2004063165 A1 WO 2004063165A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- mammal
- need
- administering
- treating
- Prior art date
Links
- 0 Cc(c(C=O)c1*)n[n]1-c1ccc(C(F)(F)F)cc1 Chemical compound Cc(c(C=O)c1*)n[n]1-c1ccc(C(F)(F)F)cc1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/04—1,2,3-Triazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Definitions
- PPARs Peroxisome Proliferator Activated Receptors
- PPAR ⁇ Three subtypes of PPARs have been isolated: PPAR ⁇ , PPAR ⁇ and PPAR ⁇ .
- each isoform differs significantly from the others, whereby PPAR ⁇ is expressed primarily, but not exclusively in liver; PPAR ⁇ is expressed primarily in adipose tissue; and PPAR ⁇ is expressed ubiquitously.
- PPAR ⁇ agonists such as pioglitazone, can be useful in the treatment of non-insulin dependent diabetes mellitus. Such PPAR ⁇ agonists are associated with insulin sensitization.
- PPAR ⁇ agonists such as fenofibrate
- PPAR ⁇ agonists can be useful in the treatment of hyperlipidemia.
- clinical evidence is not available to reveal the utility of PPAR ⁇ agonists in humans, several preclinical studies suggest that PPAR ⁇ agonists can be useful in the treatment of diabetes and lipid disorders.
- Metabolic Syndrome osteosity, insulin resistance, hyperlipidemia, hypertension and atherosclerosis
- New pharmaceutical agents are needed to address the unmet clinical needs of patients.
- PPAR ⁇ agonists have been suggested as a potential treatment for use in regulating many of the parameters associated with Metabolic Syndrome and Atherosclerosis. For example, in obese, non-diabetic rhesus monkeys, a PPAR ⁇ agonist reduced circulating triglycerides and LDL, decreased basal insulin levels and increased HDL (Oliver, W.R., et al.; Proc Natl Acad Sci 98:5306-5311; 2001).
- C-reactive protein (CRP) production is part of the acute-phase response to most forms of inflammation, infection and tissue damage. It is measured diagnostically as a marker of low-grade inflammation. Plasma CRP levels of greater than 3 mg/L have been considered predictive of high risk for coronary artery disease (J. Clin. Invest 111: 1085-1812; 2003).
- PPAR ⁇ agonists are believed to mediate anti-inflammatory effects. Indeed, treatment of LPS-stimulated macrophages with a PPAR ⁇ agonist has been observed to reduce the expression of iNOS, IL12, and IL-6 (Welch, J.S., et al.; Proc Natl Acad Sci 100:6712-67172003).
- the present invention is directed to the compound of the Formula I:
- the present invention also relates to pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and a pharmaceutically acceptable carrier.
- the present invention relates to a method of selectively modulating a PPAR delta and/or PPAR alpha receptor(s) by contacting the receptor with a compound of Formula I, or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
- the present invention relates to a method of making a compound represented by Structural Formula I.
- the compound of the present invention is believed to be effective in treating and preventing Metabolic Syndrome, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and/or other disorders related to Metabolic Syndrome and cardiovascular diseases.
- compounds of this invention can be useful for lowering fibrinogen, increasing HDL levels, treating renal disease, controlling desirable weight, treating demyelinating diseases, treating inflammatory disease including rheumatoid arthritis, asthma, Crohne's disease and psorias, treating certain viral infections, and treating liver disease. It is believed that the compound of this invention may prevent and/or reverse the clinical effects of atherosclerosis and can minimize the likelihood of future adverse cardiac events.
- the pyrazole compound can be associated with fewer clinical side effects and may have clinically significant benefits when compared to compounds currently used to treat such conditions.
- Certain compounds of Structural Formula I may exist in different stable conformational forms which may be separable. Torsional asymmetry due to restricted rotation about an asymmetric single bond, for example because of steric hindrance or ring strain, may permit separation of different conformers.
- the present invention includes each conformational isomer of compounds of Structural Formula I and mixtures thereof.
- “Pharmaceutically-acceptable salt” refers to salts of the compounds of the Structural Formula I which are considered to be acceptable for clinical and/or veterinary use.
- Typical pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention with a mineral or organic acid or an organic or inorganic base. Such salts are known as acid addition salts and base addition salts, respectively. It will be recognized that the particular counterion forming a part of any salt of this invention is not of a critical nature, so long as the salt as a whole is pharmaceutically acceptable and as long as the counterion does not contribute undesired qualities to the salt as a whole. These salts may be prepared by methods known to the skilled artisan.
- active ingredient means the compound described by Structural Formula I as well as any salts, solvates, and hydrates,
- pharmaceutically acceptable means that the carrier, diluent, excipients and salt are pharmaceutically compatible with the other ingredients of the composition.
- compositions of the present invention are prepared by procedures known in the art using well-known and readily available ingredients.
- Preventing refers to reducing the likelihood that the recipient will incur or develop any of the pathological conditions described herein.
- the term “preventing” is particularly applicable to a patient that is susceptible to the particular patholical condition.
- Treating refers to mediating a disease or condition and preventing, reversing the clinical effects of the disease, or mitigating, its further progression or ameliorate the symptoms associated with the disease or condition.
- PPAR ⁇ has been proposed to associate with and dissociate from selective co- repressors (BCL-6) that control basal and stimulated anti-inflammatory activities (Lee, C- H., et al; Science 302:453-4572003).
- BCL-6 selective co- repressors
- PPAR ⁇ agonists are thought to be useful to attenuate other inflammatory conditions such as inflammation of the joints and connective tissue as occurs in rheumatoid arthritis, related autoimmune diseases, osteroarthritis, as well as myriad other inflammatory diseases, Crohne's disease, and psoriasis.
- “Pharmaceutically-effective amount” means that amount of active ingredient, which will elicit the biological or medical response of a tissue, system, or mammal. Such an amount can be administered prophylactically to a patient thought to be susceptible to development of a disease or condition. Such amount when administered prophylactically to a patient can also be effective to prevent or lessen the severity of the mediated condition. Such an amount is intended to include an amount which is sufficient to modulate a selected PPAR receptor or to prevent or mediate a disease or condition.
- the effective amount of a Compound of Formula I will be between 0.02 through 5000 mg per day. Preferably the effective amount is between 1 through 1,500 mg per day. Preferably the dosage is from 1 through 1,000 mg per day. Most preferabley the dose is from 1 through 100 mg per day.
- the desired dose may be presented in a single dose or as divided doses administered at appropriate intervals. Dosages that are administered less frequently than daily may be effective or desired for a particular indication or patient. It may be desired that the patient is diagnosed with Metabolic Syndrome or Atherosclerosis. It is generally preferred that the patient is diagnosed by a health care provider as being in need of such treatment as claimed herein.
- a "mammal” is an individual animal that is a member of the taxonomic class Mammalia.
- the class Mammalia includes humans, monkeys, chimpanzees, gorillas, cattle, swine, horses, sheep, dogs, cats, mice, and rats. Administration to a human is most preferred.
- the compound and compositions of the present invention are useful for the treatment and/or prophylaxis of cardiovascular disease, for raising serum HDL cholesterol levels, for lowering serum triglyceride levels and/or for lower serum LDL cholesterol levels. Elevated triglyceride and LDL levels, and low HDL levels, are risk factors for the development of heart disease, stroke, and circulatory system disorders and diseases.
- the compound and compositions of the present invention can also useful for treating and/or preventing obesity.
- the compound may also be useful in the treatment of Metabolic Syndrome and its associated conditions.
- the compound and compositions of the present invention may reduce the incidence of undesired cardiac events in patients.
- the physician of ordinary skill will know how to identify humans who will benefit from administration of the compounds and compositions of the present invention.
- the invention also relates to the use of a compound of Formula I as described above, for the manufacture of a medicament for treating a PPAR receptor mediated condition.
- a therapeutically effective amount of a compound of Structural Formula I can be used for the preparation of a medicament useful for treating obesity, lowering tryglyceride levels, lowering serum LDL levels, raising the plasma level of high density lipoprotein, and for treating, preventing or reducing the risk of developing atherosclerosis, and for preventing or reducing the risk of having a first or subsequent atherosclerotic disease event in mammals, particularly in humans.
- a therapeutically effective amount of a compound of the present invention typically reduces serum triglyceride levels of a patient by about 20% or more, and increases serum HDL levels in a patient. Preferably, HDL levels will be increased by about 30% or more.
- Metabolic Syndrome includes pre-diabetic insulin resistance syndrome and the resulting complications thereof, insulin resistance, non-insulin dependent diabetes, dyslipidemia, hyperglycemia obesity, coagulopathy, hypertension and other complications associated with diabetes.
- the methods and treatments mentioned herein include the above and encompass the treatment and/or prophylaxis of any one of or any combination of the following: pre-diabetic insulin resistance syndrome, the resulting complications thereof, insulin resistance, Type II or non-insulin dependent diabetes, dyslipidemia, hyperglycemia, obesity and the complications associated with diabetes including cardiovascular disease, especially atherosclerosis.
- the methods and treatments mentioned herein include the above and encompass the treatment and/or prophylaxis of any one of or any combination of the following inflammatory and autoimmune diseases: adult r emotionalory distress syndrome, rheumatoid arthritis, demyelinating disease, Chrohne's disease, asthma, systemic lupus erythematosus, psoriasis, and bursitis.
- compositions are formulated and administered in the same general manner as detailed herein.
- the compounds of the instant invention may be used effectively alone or in combination with one or more additional active agents depending on the desired target therapy.
- Combination therapy includes administration of a single pharmaceutical dosage composition which contains a compound of Structural Formula I, a stereoisomer, salt, solvate and/or hydrate thereof ("Active Igredient") and one or more additional active agents, as well as administration of a compound of Formula I and each active agent in its own separate pharmaceutical dosage formulation.
- a Compound of Formula I and an insulin secretogogue such as biguanides, thiazolidinediones, sulfonylureas, insulin, or ⁇ -glucosidose inhibitors can be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent administered in separate oral dosage formulations.
- an Active Ingredient and one or more additional active agents can be administered at essentially the same time, i.e., concurrently, or at separately staggered times; combination therapy is understood to include all these regimens. .
- An example of combination treatment or prevention of atherosclerosis may be wherein the Active Ingredient is administered in combination with one or more of the following active agents: antihyperlipidemic agents; plasma HDL-raising agents; antihypercholesterolemic agents, fibrates, vitamins, aspirin, and the like.
- the Active Ingredient can be administered in combination with more than one additional active agents.
- Another example of combination therapy can be seen in treating diabetes and related disorders wherein the Active Ingredient can be effectively used in combination with, for example, sulfonylureas, biguanides, thiazolidinediones, ⁇ -glucosidase inhibitors, other insulin secretogogues, insulin as well as the active agents discussed above for treating atherosclerosis.
- Active Ingredient can be effectively used in combination with, for example, sulfonylureas, biguanides, thiazolidinediones, ⁇ -glucosidase inhibitors, other insulin secretogogues, insulin as well as the active agents discussed above for treating atherosclerosis.
- the Active Ingredient of the present invention have valuable pharmacological properties and can be used in pharmaceutical compositions containing a therapeutically effective amount of the Active Ingredient of the present invention, in combination with one or more pharmaceutically acceptable excipients.
- Excipients are inert substances such as, without limitation carriers, diluents, fillers, flavoring agents, sweeteners, lubricants, solubilizers, suspending agents, wetting agents, binders, disintegrating agents, encapsulating material and other conventional adjuvants. Proper formulation is dependent upon the route of administration chosen.
- Pharmaceutical compositions typically contain from about 1 to about 99 weight percent of the Active Ingredient of the present invention.
- the pharmaceutical formulation is in unit dosage form.
- a "unit dosage form” is a physically discrete unit containing a unit dose, suitable for administration in human subjects or other mammals.
- a unit dosage form can be a capsule or tablet, or a number of capsules or tablets.
- a "unit dose” is a predetermined quantity of the Active Ingredient, calculated to produce the desired therapeutic effect, in association with one or more pharmaceutically acceptable excipients.
- the quantity of the Active Ingredient in a unit dose may be varied or adjusted from about 0.1 to about 1500 milligrams or more according to the particular treatment involved. It may be preferred that the unit dosage is from about 1 mg to about 1000 mg.
- the dosage regimen utilizing the compounds of the present invention is selected by one of ordinary skill in the medical or veterinary arts, in view of a variety of factors, including, without limitation, the species, age, weight, sex, and medical condition of the recipient, the severity of the condition to be treated, the route of administration, the level of metabolic and excretory function of the recipient, the dosage form employed, the particular compound and salt thereof employed, and the like.
- compositions containing the compound of Structural Formula I or the salts thereof may be provided in dosage unit form, preferably each dosage unit containing from about 1 to about 500 mg be administered although it will, of course, . readily be understood that the amount of the compound or compounds of Structural
- Formula I actually to be administered will be determined by a physician, in the light of all the relevant circumstances.
- the compounds of the present invention are administered in a single daily dose, or the total daily dose may be administered in divided doses, two, three, or more times per day. It may be preferred to administer the Active Ingredient intermittently, i.e., less frequently than daily. When administered less frequently than daily, it may be preferred that the dosing interval is consistent. Thus, it may be preferable to dose, for example, every other day, weekly, twice monthly, monthly, and the like. Where delivery is via transdermal forms, of course, administration is continuous.
- Suitable routes of administration of pharmaceutical compositions of the present invention include, for example, oral, eyedrop, rectal, transmucosal, topical, or intestinal administration; parenteral delivery (bolus or infusion), including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraven-tricular, intravenous, intraperitoneal, intranasal, or intraocular injections.
- the compounds of the invention can also be administered in a targeted drug delivery system, such as, for example, in a liposome coated with endothelial cell-specific antibody.
- Solid form formulations include powders, tablets and capsules.
- Sterile liquid formulations include suspensions, emulsions, syrups, and elixirs.
- Pharmaceutical compositions of the present invention can be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
- the compound is radiolabelled, such as with carbon- 14, or tritiated. Said radiolabelled or tritiated compounds are useful as reference standards for in vitro assays to identify new selective PPAR receptor agonists.
- an intermediate like A is alkylated with an alkylating agent B in the presence of a base (e.g., K2CO3, Cs2CO3 etc.). Hydrolysis in the presence of aqueous NaOH or LiOH gave the acid product.
- a base e.g., K2CO3, Cs2CO3 etc.
- B LG CI, Br, I, O-para-toluenesulfonat ⁇ , O-methane sulfonate and the like
- an intermediate like A is coupled with an alcohol C under Mitsunobu reaction condition (DEAD/PPh3, ADDP/PBu3 etc.). Hydrolysis in the presence of aqueous NaOH or LiOH gave the acid product:
- the pyrazole intermediates can be made by the following method starting from ⁇ -ketoesters:
- Infrared spectra are recorded on a Perkin Elmer 781 spectrometer.
- 13 C NMR are recorded on a Varian 400 MHz spectrometer at ambient temperature.
- This aldehyde intermediate can be made by the following two methods.
- the intermediate can be obtained from two separate methods.
- Step B 3 Methyl- 1 -f4-trifluoromethyl-phenyiy 1 H-pyrazole-4-carbaldehyde
- Chlorosulfonic acid (539.92 g, 308 mL, 4.63 mol) was cooled to 0 °C and the ethyl(2-methylphenoxyacetate) (300 g, 1.54 mol) was added dropwise. The internal temperature never rose above 8 oC. Stir approximately 30 minutes more cold, then remove the bath and stir an additional 2 hours. The mixture was poured into ice water, forming a white solid, which was filtered and washed with ice water. The solid was dried under vacuum overnight (40 °C) to produce 376 g (83%) of a white solid.
- This compound can be made by the following three methods:
- Zinc iodide (105mg, 0.33mmol) was added to a solution of [3-Methyl-l-(4- trifluoromethyl-phenyl)-lH-pyrazol-4-yl]-methanol (0.65mmol) and (4-Mercapto-2- methyl-phenoxy)-acetic acid ethyl ester (176mg,0.78mmol) in 1,2-dichloroethane (1ml) and the solution stirred at ambient temperature for 1 hour. The mixture was diluted with water (20ml) and dichloromethane (10ml), the organic layer was removed, and the remaining aqueous layer extracted with dichloromethane (2 x 10ml).
- the in vitro potency of compounds in modulating PPAR receptors are determined by the procedures detailed below. DNA-dependent binding is carried out using SPA technology with PPAR receptors. Tritium-labeled PPAR ⁇ agonists are used as radioligands for generating displacement curves and IC 50 values with compounds of the invention. Cotransfection assays are carried out in CV-1 cells.
- the reporter plasmid contained an acylCoA oxidase (AOX) PPRE and TK promoter upstream of the luciferase reporter cDNA. Appropriate PPARs are constitutively expressed using plasmids containing the CMV promoter. For PPAR ⁇ , interference by endogenous PPAR ⁇ in CV-1 cells is an issue.
- a GAL4 chimeric system in which the DNA binding domain of the transfected PPAR is replaced by that of GAL4, and the GAL4 response element is utilized in place of the AOX PPRE.
- Cotransfection efficacy is determined relative to PPAR agonist reference molecules. Efficacies are determined by computer fit to a concentration-response curve, or in some cases at a single high concentration of agonist (10 ⁇ M).
- PPAR ⁇ 1800 nM
- PPAR ⁇ 2600 nM
- PPAR ⁇ 20nM
- a compound of the present invention is studied for effects upon HDL and triglyceride levels in human apoAI mice.
- transgenic for human apoAI C57BL/6-tgn(apoal)lrub, Jackson Laboratory, Bar Harbor, ME
- Mice are dosed daily by oral gavage for 8 days using a 29 gauge, 1-1/2 inch curved feeding needle (Popper & Sons).
- mice The vehicle for the controls, test compound and the positive control (fenofibrate lOOmg/kg) is 1% carboxymethylcellulose (w/v) with 0.25% tween 80 (w/v). All mice are dosed daily. Prior to termination, animals and diets are weighed and body weight change and food consumption are calculated. Three hours after last dose, mice are euthanized with CO2 and blood is removed (0.5-1.0 ml) by cardiac puncture. After sacrifice, the liver, heart, and epididymal fat pad are excised and weighed. Blood is permitted to clot and serum is separated from the blood by centrifugation.
- Cholesterol and triglycerides are measured colorimetrically using commercially prepared reagents (for example, as available from Sigma #339-1000 and Roche #450061 for triglycerides and cholesterol, respectively). The procedures are modified from published work (McGowan M. W., et al.; Clin Chem 29:538-542,1983; Allain C. C, et al.; Clin Chem 20:470-475; 1974. Commercially available standards for triglycerides and total cholesterol, respectively, commercial quality control plasma, and samples are measured in duplicate.
- Serum lipoproteins are separated and cholesterol quantitated by fast protein liquid chromatography (FPLC) coupled to an in line detection system.
- FPLC fast protein liquid chromatography
- the percent increase of HDLc serum levels in mice receiving a compound of the invention is compared to mice receiving vehicle.
- the compound of Formula 1 was examined in a dyslipidemic rhesus monkey model.
- An oral dose-escalation study for 28 days in obese, non-diabetic rhesus monkeys demonstrated an elevation of HDL-c with each dose.
- HDL cholesterol increased by more than 40% in the 3.0 mg/kg b.i.d. dose group.
- LDL cholesterol decreased by approximately 25%) in the 9.0 mg/kg b.i.d dose group, and a dose-related effect on triglycerides yielded a maximum 53% reduction in the 9.0 mg/kg b.i.d dose group.
- C- reactive protein levels were reduced compared to pretreatment levels.
- Compound of Formula 1 may be shown to elevate plasma HDL-cholesterol levels in an African Green Monkey model in a manner similar to that described above in rhesus monkeys.
- Two groups of monkeys are placed in a dose-escalating study that consists of one week of baseline measurements, 9 weeks of treatments (vehicle, Compound of Formula I), and four weeks of washout.
- monkeys in all three groups are administered vehicle once daily for seven days.
- Test compound of Formula I is administered in vehicle once daily for three weeks, then at a greater concentration (double the dose may be desired) once daily for three weeks, and then a still greater concentration (double the most recent dose may be desired) once daily for three weeks.
- monkeys in both groups are administered vehicle once daily and monitored for an additional six weeks.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/537,282 US7396850B2 (en) | 2003-01-06 | 2003-12-31 | Pyrazole derivative as PPAR modulator |
EP03815193A EP1583746A1 (en) | 2003-01-06 | 2003-12-31 | A pyrazole derivative as ppar modulator |
AU2003296401A AU2003296401A1 (en) | 2003-01-06 | 2003-12-31 | A pyrazole derivative as ppar modulator |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43856303P | 2003-01-06 | 2003-01-06 | |
US60/438,563 | 2003-01-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004063165A1 true WO2004063165A1 (en) | 2004-07-29 |
Family
ID=32713346
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/039117 WO2004063165A1 (en) | 2003-01-06 | 2003-12-31 | A pyrazole derivative as ppar modulator |
PCT/US2003/039119 WO2004063166A1 (en) | 2003-01-06 | 2003-12-31 | Heterocyclic ppar modulators |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/039119 WO2004063166A1 (en) | 2003-01-06 | 2003-12-31 | Heterocyclic ppar modulators |
Country Status (8)
Country | Link |
---|---|
US (2) | US7396850B2 (en) |
EP (2) | EP1585733A1 (en) |
AR (1) | AR042705A1 (en) |
AU (2) | AU2003296404A1 (en) |
CL (1) | CL2004000011A1 (en) |
PE (1) | PE20041039A1 (en) |
TW (1) | TW200505867A (en) |
WO (2) | WO2004063165A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007003581A1 (en) | 2005-06-30 | 2007-01-11 | Novo Nordisk A/S | Phenoxy acetic acids as ppar delta activators |
US7943613B2 (en) | 2005-12-22 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
US7943612B2 (en) | 2006-03-09 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds that modulate PPAR activity, their preparation and use |
US7968723B2 (en) | 2004-05-05 | 2011-06-28 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
US8053598B2 (en) | 2004-05-05 | 2011-11-08 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
WO2012030165A2 (en) | 2010-08-31 | 2012-03-08 | 서울대학교산학협력단 | Use of the fetal reprogramming of a ppar δ agonist |
WO2013171134A1 (en) | 2012-05-14 | 2013-11-21 | Bayer Cropscience Ag | Process for preparing 1-alkyl-3-fluoroalkyl-1h-pyrazole-4-carboxylic acid chlorides |
CN105934430A (en) * | 2014-01-24 | 2016-09-07 | 拜耳作物科学股份公司 | Method for preparing 1-alkyl-3-difluoromethyl-5-fluor-1H-pyrazole-4-carbaldehydes and 1-alkyl-3-difluoromethyl-5-fluor-1H-pyrazole-4-carboxylates |
US10456406B2 (en) | 2013-09-09 | 2019-10-29 | Vtv Therapeutics Llc | Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb |
US11931365B2 (en) | 2022-01-25 | 2024-03-19 | Reneo Pharmaceuticals, Inc. | Use of PPAR-delta agonists in the treatment of disease |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7396850B2 (en) * | 2003-01-06 | 2008-07-08 | Eli Lilly And Company | Pyrazole derivative as PPAR modulator |
NZ543375A (en) | 2003-05-01 | 2009-05-31 | Bristol Myers Squibb Co | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors |
KR100815691B1 (en) * | 2004-04-28 | 2008-03-20 | 에프. 호프만-라 로슈 아게 | Pyrazole phenyl derivatives as ppar activators |
FR2882359A1 (en) * | 2005-02-24 | 2006-08-25 | Negma Lerads Soc Par Actions S | New phenyl compounds are peroxisome proliferator activated receptor activators useful to treat hyperlipidemia and atherosclerosis |
AU2006217682A1 (en) * | 2005-02-28 | 2006-08-31 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator activating receptor delta |
WO2006126514A1 (en) | 2005-05-27 | 2006-11-30 | Shionogi & Co., Ltd. | Arylacetate derivative having isoxazole skeleton |
CA2613517A1 (en) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Pyrazole based lxr modulators |
CN101296914B (en) | 2005-08-26 | 2012-07-18 | 盐野义制药株式会社 | Derivative having PPAR agonistic activity |
CA2621406A1 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | Pparactive compounds |
ES2522291T3 (en) | 2006-04-18 | 2014-11-14 | Nippon Chemiphar Co., Ltd. | Activating agent for the receptor activated by the peroxisome proliferator |
EP2039779A1 (en) * | 2006-07-19 | 2009-03-25 | Takeda Pharmaceutical Company Limited | Screening method |
JP5399262B2 (en) | 2006-12-08 | 2014-01-29 | エグゼリクシス パテント カンパニー エルエルシー | LXR and FXR modulators |
US20100183696A1 (en) | 2007-01-30 | 2010-07-22 | Allergan, Inc | Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists |
KR20090129406A (en) * | 2007-02-23 | 2009-12-16 | 일라이 릴리 앤드 캄파니 | Peroxisome proliferator activated receptor modulators |
WO2009102761A1 (en) * | 2008-02-12 | 2009-08-20 | Bristol-Myers Squibb Company | 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type i inhibitors |
DK2277874T3 (en) | 2008-04-15 | 2018-08-06 | Nippon Chemiphar Co | ACTIVATOR FOR PEROXISOM PROLIFERATOR-ACTIVATED RECEPTOR |
CN101643451B (en) | 2008-08-07 | 2013-03-06 | 浙江海正药业股份有限公司 | Peroxisome proliferator-activated receptor subtype delta agonist compound and preparation method thereof |
US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
JP7017563B2 (en) | 2016-10-05 | 2022-02-08 | ミトブリッジ,インコーポレーテッド | Crystalline and salt morphology of PPAR agonist compounds |
CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001016120A1 (en) * | 1999-08-27 | 2001-03-08 | Eli Lilly And Company | Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2036192A1 (en) * | 1990-02-13 | 1991-08-14 | Nicholas Meanwell | Heterocyclic carboxylic acids and esters |
JP3694774B2 (en) * | 1997-10-31 | 2005-09-14 | 大鵬薬品工業株式会社 | Phenylcarboxylic acid derivatives |
AR035912A1 (en) * | 2000-03-02 | 2004-07-28 | Aventis Cropscience Sa | 4-TIOMETILPIRAZOL COMPOUNDS, PESTICIDE COMPOSITION, PEST CONTROL METHOD IN A PLACE, TREATED OR COVERED SEEDS, USE OF THESE COMPOUNDS OR COMPOSITIONS FOR PEST CONTROL, USE OF THESE COMPOUNDS TO PREPARE A MEDICINAL PRODUCT, VETERINARY PROCESS, VETERINARY THE PREPARATION OF |
KR20040030658A (en) * | 2001-06-07 | 2004-04-09 | 일라이 릴리 앤드 캄파니 | Modulators of peroxisome proliferator activated receptors(ppar) |
US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
WO2003099793A1 (en) * | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
US7396850B2 (en) * | 2003-01-06 | 2008-07-08 | Eli Lilly And Company | Pyrazole derivative as PPAR modulator |
-
2003
- 2003-12-31 US US10/537,282 patent/US7396850B2/en not_active Expired - Fee Related
- 2003-12-31 WO PCT/US2003/039117 patent/WO2004063165A1/en not_active Application Discontinuation
- 2003-12-31 US US10/540,341 patent/US20060241157A1/en not_active Abandoned
- 2003-12-31 AU AU2003296404A patent/AU2003296404A1/en not_active Abandoned
- 2003-12-31 AU AU2003296401A patent/AU2003296401A1/en not_active Abandoned
- 2003-12-31 EP EP03815195A patent/EP1585733A1/en not_active Withdrawn
- 2003-12-31 EP EP03815193A patent/EP1583746A1/en not_active Withdrawn
- 2003-12-31 WO PCT/US2003/039119 patent/WO2004063166A1/en not_active Application Discontinuation
-
2004
- 2004-01-05 CL CL200400011A patent/CL2004000011A1/en unknown
- 2004-01-05 AR ARP040100011A patent/AR042705A1/en unknown
- 2004-01-06 TW TW093100250A patent/TW200505867A/en unknown
- 2004-01-06 PE PE2004000047A patent/PE20041039A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001016120A1 (en) * | 1999-08-27 | 2001-03-08 | Eli Lilly And Company | Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7968723B2 (en) | 2004-05-05 | 2011-06-28 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
US8053598B2 (en) | 2004-05-05 | 2011-11-08 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
WO2007003581A1 (en) | 2005-06-30 | 2007-01-11 | Novo Nordisk A/S | Phenoxy acetic acids as ppar delta activators |
EP2298742A1 (en) | 2005-06-30 | 2011-03-23 | High Point Pharmaceuticals, LLC | Phenoxy acetic acids as PPAR delta activators |
US7943669B2 (en) | 2005-06-30 | 2011-05-17 | High Point Pharmaceuticals, Llc | Phenoxy acetic acids as PPAR delta activators |
US8426473B2 (en) | 2005-06-30 | 2013-04-23 | High Point Pharnaceuticals, LLC | Phenoxy acetic acids as PPAR delta activators |
US8217086B2 (en) | 2005-06-30 | 2012-07-10 | High Point Pharmaceuticals, Llc | Phenoxy acetic acids as PPAR delta activators |
US9855274B2 (en) | 2005-12-22 | 2018-01-02 | Vtv Therapeutics Llc | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists |
EP2386540A1 (en) | 2005-12-22 | 2011-11-16 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
US9663481B2 (en) | 2005-12-22 | 2017-05-30 | Vtv Therapeutics Llc | Phenoxy acetic acids and phenyl propionic acids as PPARδ agonists |
US8362016B2 (en) | 2005-12-22 | 2013-01-29 | High Point Pharmaceuticals, Llc | Phenyl propionic acids as PPAR delta activators |
US7943613B2 (en) | 2005-12-22 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
US8551993B2 (en) | 2005-12-22 | 2013-10-08 | High Point Pharmaceuticals, Llc | Phenoxy acetic acids as PPAR delta activators |
US11420929B2 (en) | 2005-12-22 | 2022-08-23 | Vtv Therapeutics Llc | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists |
US10947180B2 (en) | 2005-12-22 | 2021-03-16 | Vtv Therapeutics Llc | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists |
US10471066B2 (en) | 2005-12-22 | 2019-11-12 | Vtv Therapeutics Llc | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists |
US7943612B2 (en) | 2006-03-09 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds that modulate PPAR activity, their preparation and use |
WO2012030165A2 (en) | 2010-08-31 | 2012-03-08 | 서울대학교산학협력단 | Use of the fetal reprogramming of a ppar δ agonist |
JP2015517509A (en) * | 2012-05-14 | 2015-06-22 | バイエル・クロップサイエンス・アーゲーBayer Cropscience Ag | Process for producing 1-alkyl-3-fluoroalkyl-1H-pyrazole-4-carbonyl chlorides |
CN104254523A (en) * | 2012-05-14 | 2014-12-31 | 拜尔农作物科学股份公司 | Process for preparing 1-alkyl-3-fluoroalkyl-1h-pyrazole-4-carboxylic acid chlorides |
WO2013171134A1 (en) | 2012-05-14 | 2013-11-21 | Bayer Cropscience Ag | Process for preparing 1-alkyl-3-fluoroalkyl-1h-pyrazole-4-carboxylic acid chlorides |
KR20150008400A (en) * | 2012-05-14 | 2015-01-22 | 바이엘 크롭사이언스 아게 | Process for preparing 1-alkyl-3-fluoroalkyl-1h-pyrazole-4-carboxylic acid chlorides |
US9145369B2 (en) | 2012-05-14 | 2015-09-29 | Bayer Cropscience Ag | Process for preparing 1-alkyl-3-fluoroalkyl-1H-pyrazole-4-carboxylic acid chlorides |
KR102006518B1 (en) | 2012-05-14 | 2019-08-01 | 바이엘 크롭사이언스 악티엔게젤샤프트 | Process for preparing 1-alkyl-3-fluoroalkyl-1h-pyrazole-4-carboxylic acid chlorides |
US10456406B2 (en) | 2013-09-09 | 2019-10-29 | Vtv Therapeutics Llc | Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb |
EP3756661A1 (en) | 2013-09-09 | 2020-12-30 | vTv Therapeutics LLC | Use of a ppar-delta agonist for treating muscle atrophy |
US11096946B2 (en) | 2013-09-09 | 2021-08-24 | Vtv Therapeutics Llc | Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb |
CN105934430B (en) * | 2014-01-24 | 2018-03-16 | 拜耳作物科学股份公司 | The method for preparing the formaldehyde of 1 alkyl, 3 difluoromethyl, 5 fluorine 1H pyrazoles 4 and the formic acid esters of 1 alkyl, 3 difluoromethyl, 5 fluorine 1H pyrazoles 4 |
CN105934430A (en) * | 2014-01-24 | 2016-09-07 | 拜耳作物科学股份公司 | Method for preparing 1-alkyl-3-difluoromethyl-5-fluor-1H-pyrazole-4-carbaldehydes and 1-alkyl-3-difluoromethyl-5-fluor-1H-pyrazole-4-carboxylates |
JP2017506219A (en) * | 2014-01-24 | 2017-03-02 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | Process for preparing 1-alkyl-3-difluoromethyl-5-fluoro-1H-pyrazole-4-carbaldehydes and 1-alkyl-3-difluoromethyl-5-fluoro-1H-pyrazole-4-carboxylates |
US9656966B2 (en) | 2014-01-24 | 2017-05-23 | Bayer Cropscience Aktiengesellschaft | Method for preparing 1-alkyl-3-difluoromethyl-5-fluor-1H-pyrazole-4-carbaldehydes and 1-alkyl-3-difluoromethyl-5-fluor-1H-pyrazole-4-carboxylates |
US11931365B2 (en) | 2022-01-25 | 2024-03-19 | Reneo Pharmaceuticals, Inc. | Use of PPAR-delta agonists in the treatment of disease |
Also Published As
Publication number | Publication date |
---|---|
US20060241157A1 (en) | 2006-10-26 |
CL2004000011A1 (en) | 2005-04-15 |
EP1585733A1 (en) | 2005-10-19 |
AR042705A1 (en) | 2005-06-29 |
PE20041039A1 (en) | 2004-12-30 |
EP1583746A1 (en) | 2005-10-12 |
US20070043220A1 (en) | 2007-02-22 |
AU2003296401A1 (en) | 2004-08-10 |
US7396850B2 (en) | 2008-07-08 |
AU2003296404A1 (en) | 2004-08-10 |
WO2004063166A1 (en) | 2004-07-29 |
WO2004063166A8 (en) | 2005-03-03 |
TW200505867A (en) | 2005-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7396850B2 (en) | Pyrazole derivative as PPAR modulator | |
US7507832B2 (en) | Triazole PPAR modulators | |
US7153878B2 (en) | Peroxisome proliferator activated receptor modulators | |
JP3490704B2 (en) | Thiazole and oxazole derivatives and their pharmaceutical use | |
JP4234431B2 (en) | Thiazole and oxazole derivatives as activators of human peroxisome proliferator-activated receptors | |
CA2029703C (en) | Oxazolidinedione hypoglycemic agents | |
US5089514A (en) | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents | |
US7544707B2 (en) | Bicyclic derivatives as PPAR modulators | |
JP2006516254A (en) | Fused heterocyclic derivatives as PPAR modulators | |
SK15532001A3 (en) | Di-aryl acid derivatives as ppar receptor ligands | |
CZ20033064A3 (en) | Furan and thiophene derivatives | |
IE890738L (en) | Hypoglycemic thiazolidinedione derivatives | |
EA011010B1 (en) | Compounds modulating of gpr40 receptor, pharmaceutical composition, method for treating diseases responsive to the modulation of gpr40 receptor (embodiments), method for modulating gpr40 function (embodiments) and method for modulating circulating insulin concentration | |
JP2004532266A (en) | Thiazole or oxazole derivatives useful for treating cardiovascular diseases | |
US5036079A (en) | Hypoglycemic thiazolidinedione derivatives | |
CZ20021903A3 (en) | Substituted oxazole and thiazole derivatives functioning as HPPAR-alpha activators | |
US20090176863A1 (en) | Thiophene derivative ppar modulators | |
KR20050044606A (en) | Peroxisome proliferator activated receptor agonists | |
EP1313716B1 (en) | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists | |
US5130379A (en) | Hypoglycemic thiazolidinedione derivatives | |
JP2004517100A (en) | Substituted oxazoles and thiazoles as hPPARalpha agonists | |
DE60131001T2 (en) | OXAZOLYLARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | |
JP2002322163A (en) | Piperazine derivative | |
JP2007508270A (en) | I. A. Thiazole-2-carboxamide derivatives for use as HPPAR agonists in the treatment of dyslipidemia | |
WO1991003474A1 (en) | Hypoglycemic thiazolidinedione derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007043220 Country of ref document: US Ref document number: 10537282 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003815193 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003815193 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 10537282 Country of ref document: US |